Albany Molecular Res (NASDAQ:AMRI) shares traded -0.09% down during most recent session to reach at the closing price of $21.74. The stock exchanged hands 1.75 Million shares versus average trading capacity of 1.49 Million shares, yielding a market cap of $934.17 Million. Wall Street analysts covering the stock are projecting that the stock will reach $21 within the next 52-weeks. The mean target projections are based on 1 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Albany Molecular Res (NASDAQ:AMRI) high price target of $21 and with a conservative view have low price target of $21.

JP Morgan “Downgrades” Albany Molecular Res (NASDAQ:AMRI) in a research note issued to investors on 6/08/17 to Neutral with price target of $0.

Additionally on 5/11/17 Morgan Stanley “Downgrades” Albany Molecular Res (NASDAQ:AMRI) to Equal-Weight setting price target at $0 and on 10/26/15 First Analysis “Upgrades” the stock to Overweight. Furthermore on 12/18/14 First Analysis “Initiates Coverage on” the stock to Equal-Weight.

On the other hand the company has Relative Strength Index (RSI 14) of 74.78 along with Average True Range (ATR 14) of 0.35, Consequently Albany Molecular Res (NASDAQ:AMRI)’s weekly and monthly volatility is 0.41%, 0.52% respectively. The company’s beta value is at 1.18.

In terms of Buy, Sell or Hold recommendations, Albany Molecular Res (NASDAQ:AMRI) has analysts’ mean recommendation of 3. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Albany Molecular Res (NASDAQ:AMRI)’s minimum EPS for the current quarter is at $0.28 and can go high up to $0.3. The consensus mean EPS for the current quarter is at $0.29 derived from a total of 4 estimates from the analysts who have weighed in on projected earnings. However the company reported $0.36 earnings per share for the same quarter during last year.

Previously Albany Molecular Res (NASDAQ:AMRI) reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.01. The company posted an earnings surprise of 8.3%.

While considering growth estimates of the company, it has next quarter growth estimates of 23.5% whereas during current quarter it has -19.4% estimations over growth, comparing to the estimations of 18.9% during current year and 20.4% for next year. Past 5 years growth of Albany Molecular Res (NASDAQ:AMRI) observed at 29.35%, looking forward for the next 5 years it has a strong prediction of 10.7% over growth.

Albany Molecular Res (NASDAQ:AMRI)’s revenue estimates for the current quarter are $170.75 Million according to 3 number of analysts, for the current quarter the company has high revenue estimates of $175.66 Million in contradiction of low revenue estimates of $168 Million. For the current year the company’s revenue estimates are $722.22 Million compared to low analyst estimates of $720 Million and high estimates of $726.44 Million according to 4 number of analysts.

Currently Albany Molecular Res (NASDAQ:AMRI)’s shares owned by insiders are 8.3%, whereas shares owned by institutional owners are 75.6%. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded 1.81%.

Albany Molecular Res (NASDAQ:AMRI) 52-week high price stands at $22.17 and low price stands at $13.01, its price distance from 52-week high is -1.94% while its distance from 52-week low price is 67.1%. The stock hit its 52-week high on 06/05/17, and 52-week low on 03/23/17.

Albany Molecular Res (NASDAQ:AMRI)’s trailing twelve month revenues are $628.7 Million, whereas its price to sales ratio for the same period is 1.49. Its book value per share for the most recent quarter is $7 while its price to book ratio for the same period is 3.11, as for as the company’s cash per share for the most recent quarter is $0.82, however its price to cash per share ratio for the same period is 26.54. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.